Most relevant publications

ElHarouni D, Berker Y, Peterziel H, Gopisetty A , Turunen L, Kreth S ,Stainczyk SA, Oehme I, Pietiäinen V, Jäger N, Witt O, Schlesner M, Oppermann S. iTReX: Interactive exploration of mono- and combination therapy dose response profiling data. Pharmacol Res 2022 Jan:175:105996. doi: 10.1016/j.phrs.2021.105996.

Berker Y, ElHarouni D, …, Schlesner M, Oppermann S. Patient-by-Patient Deep Transfer Learning for Drug-Response Profiling Using Confocal Fluorescence Microscopy of Pediatric Patient-Derived Tumor-Cell Spheroids. IEEE Trans Med Imaging 2022 Dec;41(12):3981-3999, doi: 10.1109/TMI.2022.3205554

Peterziel, N. Jamaladdin, …, Oppermann S, Milde T, Witt O, Oehme I. Development of a functional patient-derived 3D multicellular platform for real-time personalized drug sensitivity profiling in the pediatric precision oncology program INFORM. npj Precis Oncol. 2022; doi: 10.1038/s41698-022-00335-y

Oppermann S, Ylanko J, et al. Identification of kinase inhibitors that overcome venetoclax resistance in activated CLL cells by high-content screening. Blood. 2016 18; 128(7):934-47, doi: 10.1182/blood-2015-12-687814.

Oppermann S, Lam AJ et al. Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells Oncotarget. 2016 Nov 8;7(45):72608-72621; doi: 10.18632/oncotarget.11618.

Zeuner S, Vollmer J, Sigaud R, Oppermann S et al. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells. J Neurooncol. 2024 Jan;166(1):99-112.doi: 10.1007/s11060-023-04526-w.

Gatzweiler C, Ridinger J, Herter S, Gerloff XF, ElHarouni D, Berker Y, Imle R, Schmitt L, Kreth S, Stainczyk S, Ayhan S, Najafi S, Krunic D, Frese K, Meder B, Reuss D, Fiesel P, Schramm K, Blattner-Johnson M, Jones DTW, Banito A, Westermann F, Oppermann S, et al. Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models. Cancers (Basel). 2022 Feb 8;14(3):849; doi: 10.3390/cancers14030849.

Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, et al. Drug-Perturbation-Based-Stratification of Blood Cancer. J Clin Invest. 2018 Jan 2;128(1):427-445. doi: 10.1172/JCI93801.